期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 33, 期 1, 页码 86-91出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0000000000000622
关键词
carbapenem; extended-spectrum beta-lactamase; intensive care; sparring carbapenem
资金
- Innovative Medicines Initiative Joint Undertaking from the European Union'sSeventh Framework Programme (FP7/2007-2013) [115523 COMBACTE]
- EFPIA companies
Purpose of review To review available data on carbapenem use in ICU. Carbapenem is a broad spectrum well tolerated antibiotic family that keep an excellent activity to extended spectrum beta-lactamases and AmpC hyperproducer and in susceptiblePseudomonas aeruginosaandAcinetobacter baumannii. It becomes a drug of choice for empirical therapy of suspected sepsis in known or presumably known ESBLE carriers. Recent findings Carbapenems remained the drug of choice for severe ESBLE infections. In severe critically ill patients, high off-label dose is necessary especially in patients with sepsis and glomerular hyperfiltration. Nevertheless, large spectrum of carbapenems leads to initial overuse. The increase in the overall consumption in the past years with lack of systematic re-evaluation observed is responsible of and carbapenem-selection pressure that contribute to the increase of carbapenem-resistant enterobacteriaceae,A. BaumanniiandP. Aeruginosain ICUs. Carbapenems remained a cornerstone of antibiotic therapy of severe infections. Emerging carbapenem resistance is related to the increase of carbapenem consumption. High doses are recommended for early therapy followed by systematic reevaluation on a daily basis with shift to narrow spectrum antimicrobials if possible and early stopping rules.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据